EQS-News: Defence Therapeutics Inc.: DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUMTM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY

_________________________________________________________________

CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE

DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUM^TM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY

Vancouver, BC, Canada, April 24, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates (“ADCs”), is pleased to announce the issuance of its US patent no. 11,612,651 by the United States Patent and Trademark Office (USPTO).

The US patent broadly covers Defence’s Accum^TM-based vaccine enhancer technology platform as a powerful “drop-in” ingredient to boost immunogenicity and performance of virtually any cell-based or protein subunit vaccine, including both prophylactic and therapeutic vaccines in the fields of cancer and infectious diseases. In particular, the ability of Defence’s vaccine enhancer technology, upon simple admixture with an antigen, to improve activation of antigen-specific CD4 and CD8 T cell responses paves the way for highly potent next-generation vaccines having reduced antigen doses.

The patent issuance not only bolsters Defence’s patent portfolio in the United States and aligns with the Company’s objectives to advance their own novel clinical vaccine candidates, but also creates new licensing and partnering opportunities due to the breadth of coverage and ease of implementation of the technology. Specifically, the demonstrated ability of Defence’s enhancer technology to increase the quality of antigen presentation by immune cells is being actively explored to improve upon existing vaccines and clinically-validated antigen candidates, such as by reducing antigen dose, thereby lowering manufacturing costs and potentially diminishing patient adverse reactions.

“The rapid granting of this broad patent by the USPTO is a testament to the innovative nature and quality of the underlying science behind Defence’s Accum^TM technology. The Company has plans to leverage the USPTO’s approval to secure global patent protection in all key vaccine markets, including infectious diseases and cancers, and to capitalize notably on the current mRNA boom in the vaccine development market”, says Mr. Sebastien Plouffe, the CEO of Defence Therapeutics.

Defence’s current vaccines in development programs using its Accum^TM technology includes notably its 100% owned cell-based ARM vaccine targeting solid cancer tumors, the AccuTOX^TM small molecule targeting melanoma, breast and lung cancers, AccuVAC-PT007, a prophylactic and therapeutic protein-based vaccine targeting cervical cancer, as well as mRNA vaccines for multiple indications. Defence’s also has positive validation on vaccines developed for certain infectious disease and is currently planning a novel vaccine using its Accum^TM technology on a worldwide life-threatening disease on which a press release will be issued on further advancement.

According to Fortune Business Insights, the global vaccines market is projected to grow from $61.04 billion in 2021 to $125.49 billion in 2028 at a CAGR of 10.8% in forecast period, 2021-2028.

https://www.fortunebusinessinsights.com/industry-reports/vaccines-market...

About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

[email protected]

www.defencetherapeutics.com

Cautionary Statement Regarding “Forward-Looking” Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.